Travere Therapeutics (TVTX) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Travere Therapeutics published the results on November 2, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Travere Therapeutics reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP, per basic share, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Travere's Q3 2026 loss includes a $113.1 million in-process research and development expense from closing its license agreement with Everest Medicines for civorebrutinib.
• Year-ago license and collaboration revenue included a $40.0 million CSL Vifor market access milestone and $9.3 million recognized when Chugai relinquished a buyout right.
• Travere does not publish a revenue or earnings outlook in its release.

Source: Travere Therapeutics Q3 2026 results, November 2, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Travere Therapeutics splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Travere Therapeutics's FILSPARI revenue was $200 million in Q3 2026, up 120% from $90.9 million in Q3 2025, 89% of total revenue.
• Travere Therapeutics's Tiopronin products revenue was $20.0 million in Q3 2026, down 10% from $22.3 million in Q3 2025, 9% of total revenue.
• Travere Therapeutics's License and collaboration revenue revenue was $4.4 million in Q3 2026, down 92% from $51.7 million in Q3 2025, 2% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

Total revenue and diluted net income (loss) per share, each as first reported in that quarter's release.

We do not hold a confirmed date for Travere Therapeutics's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 2, 2026

Travere Therapeutics had total revenue of $224.6 million in Q3 2026, against $164.9 million a year earlier. U.S. net product sales were $220.2 million, of which FILSPARI (sparsentan) brought in $200.2 million, up 120% year over year, and tiopronin products $20.0 million, down from $22.2 million. License and collaboration revenue was $4.4 million. (Travere Therapeutics Q3 2026 release (8-K Exhibit 99.1), Nov 2, 2026)

Travere sells FILSPARI for IgA nephropathy and, since the FDA's full approval on April 13, 2026, for FSGS without nephrotic syndrome in patients aged 8 and older. The 10-Q says FILSPARI is the first and only medicine approved by the FDA for FSGS. Thiola and Thiola EC (tiopronin) treat cystinuria, a rare genetic disorder that causes recurring kidney stones. (Travere Therapeutics Form 10-Q, Q3 2026, Nov 2, 2026; Travere Therapeutics Form 10-K, 2025, Feb 19, 2026)

Travere received 1,932 new patient start forms for FILSPARI across IgAN and FSGS in Q3 2026. CEO Eric Dube said the company remains early in reaching the more than 100,000 addressable patients across the two conditions. (Travere Therapeutics Q3 2026 release (8-K Exhibit 99.1), Nov 2, 2026)

Travere's license and collaboration revenue fell from $51.7 million because the year-ago quarter included a $40.0 million market access milestone under the CSL Vifor License Agreement and $9.3 million recognized when Chugai relinquished its buyout right. CSL Vifor licenses FILSPARI in Europe, where the European Commission granted it conditional marketing authorization in April 2024. (Travere Therapeutics Form 10-Q, Q3 2026, Nov 2, 2026)

Travere Therapeutics lost $52.3 million, or $0.55 per diluted share, in Q3 2026, against net income of $25.7 million, or $0.28 per diluted share, a year earlier. The quarter carries a $113.1 million IPR&D expense from closing its exclusive license for civorebrutinib with Everest Medicines. The loss from continuing operations was $0.64 per share, partly offset by $8.7 million of income from discontinued operations. (Travere Therapeutics Q3 2026 release (8-K Exhibit 99.1), Nov 2, 2026; Travere Therapeutics Form 10-Q, Q3 2026, Nov 2, 2026)

On Travere's non-GAAP basis the net loss was $29.6 million, or $0.31 per basic share. The non-GAAP figures add back stock compensation ($7.1 million in R&D and $16.3 million in SG&A), depreciation and royalty amortization of $4.8 million, and remove the income tax benefit of $5.9 million. They do not exclude the IPR&D expense. (Travere Therapeutics Q3 2026 release (8-K Exhibit 99.1), Nov 2, 2026)

R&D expense rose to $70.3 million from $51.9 million, mainly for the Phase 3 HARMONY Study and manufacturing of pegtibatinase, and SG&A rose to $98.4 million from $71.0 million on the FSGS launch and IgAN commercialization. Basic weighted average shares were 94,627,788, against 89,230,420 a year earlier. (Travere Therapeutics Q3 2026 release (8-K Exhibit 99.1), Nov 2, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Travere Therapeutics does not publish a revenue or earnings outlook in its release. It gives program timelines instead: topline data from the Phase 3 HARMONY Study of pegtibatinase in classical homocystinuria are anticipated in 2H 2027, a U.S. IND for civorebrutinib is planned by year-end, and data from the SPARX Study of FILSPARI in post-transplant patients are anticipated in 2027. (Travere Therapeutics Q3 2026 release (8-K Exhibit 99.1), Nov 2, 2026)

Bradley L. Campbell succeeds Eric Dube as president and chief executive officer effective December 1, 2026. Travere had cash, cash equivalents and marketable securities of $471.8 million at September 30, 2026. (Travere Therapeutics Q3 2026 release (8-K Exhibit 99.1), Nov 2, 2026)

A consensus figure is the average of the models published by the analysts who cover Travere Therapeutics, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Travere Therapeutics's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning TVTX is on is TVTX a buy or a sell?, what analysts expect next is on the TVTX forecast, and what the company does is on the Travere Therapeutics (TVTX) stock page.

Every number on this page can be traced to a document Travere Therapeutics published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.